» Articles » PMID: 8756624

Cyclin-binding Motifs Are Essential for the Function of P21CIP1

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 1996 Sep 1
PMID 8756624
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

The cyclin-dependent kinase (Cdk) inhibitor p21 is induced by the tumor suppressor p53 and is required for the G1-S block in cells with DNA damage. We report that there are two copies of a cyclin-binding motif in p21, Cy1 and Cy2, which interact with the cyclins independently of Cdk2. The cyclin-binding motifs of p21 are required for optimum inhibition of cyclin-Cdk kinases in vitro and for growth suppression in vivo. Peptides containing only the Cy1 or Cy2 motif partially inhibit cyclin-Cdk kinase activity in vitro and DNA replication in Xenopus egg extracts. A monoclonal antibody which recognizes the Cy1 site of p21 specifically disrupts the association of p21 with cyclin E-Cdk2 and with cyclin D1-Cdk4 in cell extracts. Taken together, these observations suggest that the cyclin-binding motif of p21 is important for kinase inhibition and for formation of p21-cyclin-Cdk complexes in the cell. Finally, we show that the cyclin-Cdk complex is partially active if associated with only the cyclin-binding motif of p21, providing an explanation for how p21 is found associated with active cyclin-Cdk complexes in vivo. The Cy sequences may be general motifs used by Cdk inhibitors or substrates to interact with the cyclin in a cyclin-Cdk complex.

Citing Articles

The Emerging Role of p21 in Diabetes and Related Metabolic Disorders.

Elmitwalli O, Darwish R, Al-Jabery L, Algahiny A, Roy S, Butler A Int J Mol Sci. 2024; 25(23).

PMID: 39684919 PMC: 11641910. DOI: 10.3390/ijms252313209.


Investigating the p21 Ubiquitin-Independent Degron Reveals a Dual Degron Module Regulating p21 Degradation and Function.

Riutin M, Erez P, Adler J, Biran A, Myers N, Shaul Y Cells. 2024; 13(19.

PMID: 39404432 PMC: 11476297. DOI: 10.3390/cells13191670.


Senescence and SASP Are Potential Therapeutic Targets for Ischemic Stroke.

Ouvrier B, Ismael S, Bix G Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543098 PMC: 10973994. DOI: 10.3390/ph17030312.


L.: Ethnobotany, Phytochemistry, Phytonanotechnology, and Commercial Application.

Kumar S, Kumar S, Vishnoi V, Kumar P, Maheshwari D Curr Pharm Biotechnol. 2023; 25(7):838-859.

PMID: 37861013 DOI: 10.2174/0113892010262937230919100024.


Emerging approaches to CDK inhibitor development, a structural perspective.

Hope I, Endicott J, Watt J RSC Chem Biol. 2023; 4(2):146-164.

PMID: 36794018 PMC: 9906319. DOI: 10.1039/d2cb00201a.


References
1.
Pan Z, Reardon J, Li L, Flores-Rozas H, LEGERSKI R, Sancar A . Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem. 1995; 270(37):22008-16. DOI: 10.1074/jbc.270.37.22008. View

2.
Deng C, Zhang P, Harper J, Elledge S, Leder P . Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995; 82(4):675-84. DOI: 10.1016/0092-8674(95)90039-x. View

3.
Krek W, Xu G, Livingston D . Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 1995; 83(7):1149-58. DOI: 10.1016/0092-8674(95)90141-8. View

4.
Chen I, Akamatsu M, Smith M, Lung F, Duba D, Roller P . Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene. 1996; 12(3):595-607. View

5.
Lin J, Reichner C, Wu X, Levine A . Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol. 1996; 16(4):1786-93. PMC: 231165. DOI: 10.1128/MCB.16.4.1786. View